Cough Assist Devices Market - By Product Type, By Choice of Delivery, By End Use - Global Forecast, 2025 - 2034

Cough Assist Devices Market Size

The global cough assist devices market was estimated at USD 242.8 million in 2024. The market is expected to grow from USD 262.3 million in 2025 to USD 475.6 million in 2034, growing at a CAGR of 6.8%. The market is driven due to the fact that chronic respiratory disorders are common, the elderly population grows in number, and people become more aware of non-intrusive airway clearance therapies. Developments in device technology, growing home healthcare adoption, and favorable reimbursement policies further accelerate demand, improving patient outcomes and reducing hospitalization rates worldwide.

Specialized respiratory care tools like cough assist devices help clear airway secretions in patients who have neuromuscular and pulmonary conditions. Significant players include Philips, Baxter, West Care Medical, Ventec Life Systems, PARI, and Air Liquide Healthcare. The market is rising due to growing prevalence of chronic respiratory diseases, growing home healthcare adoption, and technological advancements in non-invasive airway clearance solutions.
 

The market reached from USD 183.8 million in 2021 to USD 223.7 million in 2023. Demographic, clinical, also technological drivers are reshaping respiratory care worldwide. The market is seeing steady growth as it undergoes all of these changes. One of the key factors driving the market is the rising prevalence of chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, and neuromuscular conditions like amyotrophic lateral sclerosis (ALS) and muscular dystrophy, which impair patients’ ability to effectively clear airway secretions. As the global elderly population continues to grow, the incidence of such conditions is increasing, leading to higher demand for effective airway clearance solutions. Another significant driver is the growing preference for non-invasive therapies that reduce complications and improve patient comfort compared to invasive suctioning procedures.
 

Cough assist devices, designed to provide mechanical insufflation-exsufflation, are gaining traction for their ability to minimize hospitalizations and improve quality of life. Advancements in device technology, such as portable and programmable cough assist systems, are further enhancing adoption, particularly in home healthcare settings where convenience and independence are critical for patients. Additionally, rising awareness among patients, caregivers, and healthcare professionals about the benefits of early respiratory intervention has boosted utilization across hospitals, clinics, and homecare environments.
 

Supportive reimbursement policies in developed markets and the gradual expansion of healthcare access in emerging regions are also playing a pivotal role in driving market growth. Moreover, strategic initiatives by leading players like Philips, Baxter, and Air Liquide Healthcare, including product innovation, partnerships, and expanded distribution networks, are strengthening the availability and affordability of these devices.
 

Cough assist devices are specialized smart medical devices designed to help patients clear mucus and secretions from their airways when they are unable to cough effectively on their own. These devices use a technique called mechanical insufflation-exsufflation, which delivers positive pressure to the lungs followed by rapid negative pressure, simulating a natural cough.
 

Cough Assist Devices Market Trends

The increasing prevalence of chronic respiratory diseases drives the evolution of the cough assist devices market strongly since it generates sustained demand for non-intrusive airway clearance solutions across the world. Conditions such as chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, and cystic fibrosis affect millions globally, while neuromuscular disorders such as amyotrophic lateral sclerosis (ALS) and muscular dystrophy further contribute to the burden of impaired cough reflex and mucus clearance.
 

• According to various global health agencies, COPD on its own is projected to become the third leading cause for death in the world. This forecast shows precisely how well respiratory support technologies need to work for the pressing need. Cough assist devices have a major role in improving lung hygiene. These devices stop repeated infections, lower hospitalization, and raise patient life quality. From a macroeconomic standpoint, fast urbanization occurs as air pollution deteriorates, inhabitants eat tobacco, also inhabitants age, which drives a higher acceptance of respiratory care devices because these factors fuel the incidence of chronic respiratory conditions.
   
• Additionally, rising healthcare expenditures in developed and emerging economies, coupled with favorable government initiatives and reimbursement frameworks in advanced markets, are supporting broader access to such devices. On the microeconomic side, technological innovation by leading players like Philips, Baxter, and Air Liquide Healthcare is accelerating device adoption through portable, programmable, and patient-friendly models suitable for both hospital and homecare environments.
   
• Increasing awareness among healthcare providers, caregivers, and patients about early intervention in chronic respiratory care is also improving demand, while strategic collaborations and distribution partnerships are expanding market penetration in underserved regions. However, affordability challenges remain in lower-income countries, where out-of-pocket healthcare spending is high and reimbursement coverage is limited.
   
• Overall, the rising global burden of chronic respiratory diseases, supported by macro-level demographic and environmental shifts and micro-level innovations and awareness, will continue to propel the market forward.
   

Cough Assist Devices Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The global cough assist devices market reached from USD 183.8 million in 2021 to USD 223.7 million in 2023, driven by the rising prevalence of chronic respiratory diseases and increasing demand for advanced airway clearance solutions.
 

Based on the product type, the market is bifurcated into automatic cough assist device, and manual cough assist device. The automatic cough assist device segment accounted for 72.2% of the market in 2024 driven by their advanced programmability, easier use, along with better efficiency in secretion clearing compared to manual alternatives. The segment is expected to exceed USD 347.9 million by 2034, growing at a CAGR of 7% during the forecast period. On the other hand, manual cough assist device segment is expected to grow with a CAGR of 6.4%. The growth of the segment is driven by their affordability, portability, and increasing adoption in low-resource healthcare settings.
 

• The automatic cough assist device segment grows strongly since the demand for advanced non-intrusive airway clearance solutions rises. These solutions offer much higher efficiency as well as comfort to the patients in comparison with the manual alternatives. These devices are equipped with programmable pressure settings, customizable cycles, and digital interfaces, enabling clinicians to deliver personalized therapy for patients with varying severity of respiratory or neuromuscular conditions.
   
• Their ease of use reduces dependency on caregivers and minimizes the risk of inconsistent therapy, making them highly suitable for both hospital and homecare settings. Growing awareness among healthcare providers about the clinical benefits of automated insufflation-exsufflation therapy, coupled with supportive reimbursement policies in developed countries, further drives adoption.
   
• Additionally, technological innovations such as portable and compact models with battery backup have enhanced patient mobility and broadened usage in long-term care and home environments.
   
• The manual cough assist device segment, though smaller with a market share of 27.8%, is expected to grow at a CAGR of 6.4%, driven by its affordability, portability, and increasing adoption in low-resource healthcare settings where cost is a critical factor. Manual devices are simple to operate, lightweight, and require no power source, making them especially valuable in rural and developing regions with limited access to advanced medical technologies. Their cost-effectiveness also makes them a preferred option for patients and providers in markets with limited or inconsistent reimbursement coverage.
   

Based on the choice of delivery, the cough assist devices market is segmented into mouth piece, face mask, and adapter. The mouth piece segment accounted for the highest market share of 45.8% in 2024 due to its convenience, patient comfort, and suitability as respiratory therapies for use in hospitals and homes.
 

• One of the primary drivers exists since it suits both therapies hospitals provide with home healthcare uses, so people prefer it for chronic respiratory patients also those who have neuromuscular disorders. Mouthpieces provide a non-invasive, user-friendly interface that enhances patient comfort and independence, reducing reliance on caregivers and invasive suctioning methods.
   
• They are less costly than other choices for delivery, so they are more reachable. Affordability has influence upon the adoption that occurs especially in some regions. Technological advancements have also improved ergonomics, hygiene, and portability, encouraging broader utilization.
   
• The segment’s growth is further supported by rising demand for home-based respiratory therapies, particularly among aging populations seeking fewer complex devices.
   
• The second-largest segment, face mask, held a market share of 34.8% in 2024, driven by its ability to serve patients unable to effectively seal or use mouthpieces, including children, elderly patients, and those with neuromuscular weaknesses. Its primary advantage lies in universal applicability, allowing treatment without requiring active patient coordination, which significantly improves clinical outcomes for vulnerable populations.
   
• In hospitals and emergency care settings, face masks enable rapid and effective airway clearance, reducing the risk of respiratory infections and associated complications. Growing prevalence of chronic respiratory disorders and increasing hospitalization rates have further reinforced demand for face masks.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the end use, the cough assist devices market is segmented into hospitals, homecare settings, and other end users. The hospitals segment accounted for the highest market share of 40.9% in 2024 due to increasing patient admissions, preference for advanced respiratory care, and availability of skilled healthcare professionals.
 

• The top two end use segments represent 78.4% of total market value. Increasing hospital admissions for conditions like COPD exacerbations, cystic fibrosis, and pneumonia create consistent demand for non-invasive airway clearance therapies. Hospitals prefer advanced cough assist devices for their programmable features, reliability, and ability to deliver high therapeutic efficiency under clinical supervision. The presence of trained healthcare professionals ensures optimal usage, improved patient outcomes, and adherence to treatment protocols.
   
• Additionally, government support, insurance reimbursement policies, and hospital budgets allocated for modern respiratory care equipment encourage adoption. Hospitals also serve as centers for clinical research and pilot programs, enabling rapid integration of next-generation devices. The combination of patient volume, clinical expertise, and institutional support drives the segment’s dominance, making it a critical growth engine within the global cough assist devices market.
   
• The homecare settings segment, though smaller with a market share of 37.5%, is expected to grow at a CAGR of 7.2%. Patients with chronic respiratory disorders and neuromuscular conditions increasingly prefer receiving therapy at home to avoid frequent hospital visits and reduce infection risk. Portable and user-friendly cough assist devices allow caregivers or patients themselves to perform effective airway clearance, promoting adherence and long-term health outcomes.
   
• Advances in telehealth and remote monitoring technologies further enhance the appeal of homecare solutions by enabling clinicians to track therapy progress and adjust protocols remotely. Aging populations, particularly in developed countries, are contributing to the increased demand for home-based respiratory support, while supportive reimbursement policies and insurance coverage in key markets further facilitate adoption.
   

Looking for region specific data?

Download Free PDF

North America dominated the global cough assist devices market with the highest market share of 36.8% in 2024.
 

• The U.S. market was valued at USD 65 million and USD 71.9 million in 2021 and 2022, respectively. In 2024 the market size reached USD 83.6 million from USD 77.7 million in 2023. The market is mainly driven because chronic respiratory conditions happen to be highly popular with COPD, with asthma, with cystic fibrosis, and also with neuromuscular disorders impairing clearance of airway secretions for patients. An aging population with weakened respiratory function further amplifies demand for non-invasive airway clearance solutions.
   
• Hospitals along with homecare settings actively adopt advanced, programmable cough assist devices to improve patient outcomes. These devices also lower long-term health care charges and also lessen hospitalizations. The U.S. aids from well-established health care infrastructure, robust reimbursement policies, and high insurance coverage, enabling wider accessibility and adoption of these devices.
   
• Additionally, technological advancements, including portable and battery-powered models, integration with telehealth platforms, and digital adherence monitoring, support home-based therapy, increasing market penetration. Awareness campaigns among patients and healthcare providers regarding early intervention for chronic respiratory disorders further drive adoption.
   
• Strategic initiatives by major market players, including Philips, Baxter, and Air Liquide Healthcare, through partnerships, product innovations, and clinical collaborations, enhance distribution networks and ensure steady supply.
  
   

Europe Cough Assist Devices Market
 

Europe cough assist devices market accounted for USD 69.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe’s market growth is propelled by rising prevalence of chronic respiratory and neuromuscular conditions across both Western and Eastern European countries. Countries such as Germany, France, and the U.K. have high incidences of COPD and cystic fibrosis, coupled with an aging population, which increases the demand for airway clearance therapies. European healthcare systems emphasize preventive care, reducing hospitalizations, and improving quality of life, making hospitals and homecare adoption of cough assist devices a priority.
   
• Strong reimbursement policies, government initiatives, and public health programs support the affordability and accessibility of advanced respiratory care technologies. Technological innovation, including portable, battery-operated, and user-friendly devices, drives adoption in homecare settings, enabling patients to manage chronic conditions independently.
   

Germany dominates the European cough assist devices market, showcasing strong growth potential.
 

• Germany represents one of the largest markets in Europe, driven by a combination of demographic, clinical, and technological factors. Germany’s aging population, increasing life expectancy, and high incidence of respiratory complications among elderly patients further support market growth. The country benefits from a robust healthcare system with comprehensive insurance coverage and reimbursement policies, which facilitate accessibility and adoption of advanced medical devices in hospitals, rehabilitation centers, and homecare settings.
   
• Technological advancements, including portable, programmable, and telehealth-integrated cough assist devices, enhance patient compliance and clinical outcomes. Hospitals and homecare providers are increasingly adopting these solutions to reduce complications, prevent hospital readmissions, and optimize healthcare resources.
   
• Additionally, high awareness among healthcare professionals regarding early intervention in respiratory care, coupled with ongoing clinical research and partnerships with global device manufacturers, accelerates adoption.
   

Asia Pacific Cough Assist Devices Market
 

The Asia Pacific cough assist devices market is anticipated to grow at the highest CAGR of 8.1% during the analysis timeframe.
 

• Rapid urbanization, because of how air pollution increases, and because smoking is quite popular, COPD and asthma have a burden that is higher across countries such as China, India, Japan, and South Korea. The large patient pool in the region supports the adoption of the cough assist devices. Expanding healthcare infrastructure as well as increasing government initiatives improve respiratory care, also contributing to this adoption.
   
• Home healthcare services gain traction throughout developed markets like Japan and Australia, while emerging markets benefit as hospitals invest more and clinical services improve. Technological advancements, including portable, battery-powered devices, telehealth-enabled monitoring, and user-friendly interfaces, are driving adoption among patients and caregivers.
   
• Rising healthcare expenditure, growing health insurance penetration, and strategic collaborations between global and regional manufacturers, such as Philips, Baxter, Air Liquide, and Breas Medical, strengthen distribution networks and accessibility.
   

China Cough Assist Devices market is estimated to grow with a significant CAGR, in the Asia Pacific Cough Assist Devices.
 

• China’s cough assist devices market is experiencing robust growth due to the high prevalence of chronic respiratory diseases, including COPD, asthma, and bronchiectasis, exacerbated by rapid urbanization and air pollution. Increasing neuromuscular disorders, particularly among the aging population, further drive demand for non-invasive airway clearance therapies.
   
• Expanding healthcare infrastructure, hospital modernization, and rising homecare adoption support market growth, while government initiatives to improve respiratory care accessibility and chronic disease management enhance device utilization.
   
• Technological advancements, such as portable, battery-powered, and telehealth-enabled cough assist devices, are increasingly adopted in urban centers, enabling better patient compliance and remote monitoring. Growing awareness among healthcare professionals and patients regarding early intervention and preventive respiratory care encourages adoption.
  
   

Latin American Cough Assist Devices Market
 

Brazil leads the Latin American cough assist devices market, exhibiting remarkable growth during the analysis period.
 

• Brazil’s market is driven because chronic respiratory conditions are increasingly common including COPD asthma along with cystic fibrosis as neuromuscular disorders affect airway clearance. The country’s large and aging population increases the incidence of respiratory complications, prompting hospitals, homecare providers, and long-term care facilities to adopt advanced airway clearance solutions.
   
• Expansion of healthcare infrastructure, government initiatives for chronic disease management, and growing access to public and private health insurance schemes further support market growth. Technological advancements, including portable, battery-operated, and telehealth-integrated cough assist devices, are enabling home-based therapy, reducing hospitalization rates and improving patient quality of life.
   
• Awareness programs targeting patients and caregivers about early intervention in chronic respiratory care drive adoption in both urban and semi-urban regions.
  
   

Middle East and Africa Cough Assist Devices Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Chronic respiratory diseases are increasingly popular ones in Saudi Arabia, with conditions such as COPD, asthma, and even bronchiectasis. Cases of neuromuscular disorder are also rising, and this fuels growth in the cough assist devices market. The country’s aging population and high incidence of smoking-related respiratory complications further drive demand for effective airway clearance therapies.
   
• Expansion of modern healthcare infrastructure, increased hospital capacities, and the adoption of advanced medical technologies in homecare and long-term care settings support market growth. Government initiatives under Vision 2030, including healthcare modernization and improved chronic disease management, enhance accessibility and affordability of respiratory devices.
   
• Technological innovations, such as portable, battery-operated, and telehealth-enabled cough assist devices, are increasingly adopted, improving patient compliance and reducing hospital visits.
   

Cough Assist Devices Market Share

Leading companies like Philips, Baxter, Air Liquide Healthcare, Smiths Medical (ICU Medical), and Ventec Life Systems together hold between 55% of the market share in the moderately consolidated global market. This indicates a competitive landscape where a handful of established multinational companies dominate, while smaller regional and niche players capture the remaining market. The dominance of these top players is driven by their strong brand presence, extensive distribution networks, robust research and development capabilities, and diversified product portfolios that cater to both hospital and homecare segments. Their ability to offer advanced, programmable, and patient-friendly devices with integration into telehealth and digital monitoring platforms provides a competitive advantage, ensuring widespread adoption and customer loyalty.
 

Despite the strong presence of leading companies, the market is fragmented among regional manufacturers, emerging innovators, and specialized respiratory device providers. These smaller players often focus on niche markets, cost-effective solutions, or portable devices suited for homecare, thereby gradually expanding their footprint in developing regions and underserved markets. The presence of these competitors ensures continuous innovation, price competition, and the development of patient-centric technologies, which collectively drive overall market growth.
 

Overall, the market’s moderate consolidation reflects a balance between established global leaders and agile regional players, fostering both stability and innovation. While the top companies maintain leadership through scale, expertise, and global reach, the fragmented segment encourages technological advancements, regional expansion, and competitive pricing strategies, shaping a dynamic and evolving market globally.
 

Cough Assist Devices Market Companies

Few of the prominent players operating in the cough assist devices industry include:

• ABM Respiratory Care
• Air Liquide Healthcare
• Baxter
• Breas Medical
• Dima Italia
• PARI
• Philips
• Physio Assist (Simeox)
• Seoil Pacific
• Smith’s Medical (ICU Medical)
• Ventec Life Systems
• Vitalograph
• West Care Medical

• Philips

Philips leads the cough assist devices market with a share of 18.5% in 2024. Philips’ USP lies in its advanced CoughAssist E70 device, combining programmable insufflation-exsufflation therapy with reliability, ease of use, and global hospital-homecare reach. Its strong research and development capabilities, integration with telehealth platforms, and comprehensive respiratory care portfolio ensure superior patient outcomes, widespread adoption, and leadership in the market.
 

• Baxter

Baxter’s USP is its established expertise in respiratory care, offering clinically validated, high-performance cough assist devices for hospitals and homecare. The company leverages strong distribution networks, patient-centric design, and continuous innovation to enhance therapeutic efficacy, safety, and accessibility, positioning it as a trusted provider of airway clearance solutions globally.
 

• Air Liquide Healthcare

Air Liquide Healthcare’s USP centers on its integrated respiratory care solutions, strong European presence, and homecare-focused device offerings. With expertise in patient support, robust service networks, and technologically advanced cough assist systems, the company provides personalized, reliable, and effective airway clearance therapy, strengthening adoption and market position worldwide.
 

Cough Assist Devices Industry News:

• In September 2024, Baxter International launched its next-generation airway clearance system, the Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference, enhancing therapy for patients with chronic respiratory conditions.
   
• In December 2024, Inogen Inc. received U.S. FDA 510(k) clearance for the SIMEOX 200 airway clearance device, designed to support effective treatment of patients with chronic respiratory diseases across the U.S.
   
• In July 2020, Hillrom introduced two respiratory therapy devices: the VolaraTM System for hospital-grade oscillation and lung expansion (OLE) therapy, and the SynclaraTM Cough System, enhancing airway clearance and patient respiratory care.
   
• In March 2020, ABM Respiratory Care obtained FDA clearance for its BiWaze Cough device, developed to efficiently clear bronchopulmonary secretions and support patients with impaired airway function.
   

The cough assist devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Automatic cough assist device
• Manual cough assist device

Market, By Choice of Delivery

• Mouth piece
• Face mask
• Adapter

Market, By End Use

• Hospitals
• Home care settings
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE